` CUBT (Curative Biotechnology Inc) vs S&P 500 Comparison - Alpha Spread

CUBT
vs
S&P 500

Over the past 12 months, CUBT has underperformed S&P 500, delivering a return of -40% compared to the S&P 500's 9% growth.

Stocks Performance
CUBT vs S&P 500

Loading
CUBT
S&P 500
Add Stock

Performance Gap
CUBT vs S&P 500

Loading
CUBT
S&P 500
Difference
www.alphaspread.com

Performance By Year
CUBT vs S&P 500

Loading
CUBT
S&P 500
Add Stock

Competitors Performance
Curative Biotechnology Inc vs Peers

S&P 500
CUBT
AMGN
ALNY
ARGX
603259
Add Stock

Curative Biotechnology Inc
Glance View

Market Cap
8.3m USD
Industry
N/A

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The firm's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a immune therapy to treat rabies. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation to treat degenerative eye disease.

CUBT Intrinsic Value
Not Available
C
Back to Top